Stay updated on Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial
Sign up to get notified when there's something new on the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page.

Latest updates to the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant changes, including the removal of the primary objective of a study on Sjogren's Syndrome and the associated key inclusion and exclusion criteria, while retaining some drug names and collaborators.SummaryDifference7%
- Check31 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check38 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check88 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib, Lanraplenib & Tirabrutinib in Sjogren's Clinical Trial page.